Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil for Mild Cognitive Impairment in Parkinson's Disease
2024-510959-35-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Donepezil (Aricept) with Placebo (2 arms). Primary endpoints: Parkinson's Disease-Cognitive Rating Scale (PD-CRS) and Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS). Planned start Jun 2024; status: authorised.
02
Drugs
donepezil
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2024-510959-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510959-35-00.